Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
    1.
    发明公开
    Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 审中-公开
    提取,完全人性化的HuCAL-GOLD(RTM)衍生的分析特异于人CD38抗体治疗

    公开(公告)号:EP2799451A1

    公开(公告)日:2014-11-05

    申请号:EP14164595.2

    申请日:2006-05-24

    申请人: MorphoSys AG

    IPC分类号: C07K16/28 A61P35/00

    摘要: The invention pertains to a human or humanized anti-CD38 antibody or functional fragment thereof for use in a method of treating a tumor disease, in particular a haematological disease, by inducing specific killing of tumor cells that express CD38 by CD38 cross-linking. The antibody for use according to the invention include an antibody characterized by a variable heavy chain having the amino acid sequence of SEQ ID NO:6 and a variable light chain having the amino acid sequence of SEQ ID NO:14, an antibody characterized a variable heavy chain having the amino acid sequence of SEQ ID NO:5 and a variable light chain having the amino acid sequence of SEQ ID NO:13 as well as variants thereof.

    摘要翻译: 本发明涉及的人或人源化抗CD38抗体或其用于治疗肿瘤疾病,特别是血液学疾病的方法使用功能性片段,通过诱导肿瘤细胞的特异性杀伤并通过CD38交联快递CD38。 使用雅丁到本发明的抗体包括由具有SEQ ID NO:2的氨基酸序列的可变重链为特征的抗体:6和具有SEQ ID NO:2的氨基酸序列的可变轻链:14,在抗体为特征的一个变量 5和具有SEQ ID NO:2的氨基酸序列的可变轻链:13以及它们的变体具有SEQ ID NO:2的氨基酸序列的重链。